You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 9, September 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neoplasms
 •Prognosis/ Outcomes
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Hematology/ Hematologic Malignancies
 •Leukemias/ Lymphomas
 •Alert me on articles by topic

Analysis of T-Cell Receptor Gene Rearrangement for Predicting Clinical Outcome in Patients With Cutaneous T-Cell Lymphoma

A Comparison of Southern Blot and Polymerase Chain Reaction Methods

Thaddeus Juarez, MD; Scott N. Isenhath, MD; Nayak L. Polissar, PhD; Daniel E. Sabath, MD, PhD; Brent Wood, MD, PhD; Deena Hanke, BS, MS; Claire L. Haycox, MD, PhD; Gary S. Wood, MD, PhD; John E. Olerud, MD

Arch Dermatol. 2005;141:1107-1113.

Objective  To extend previous observations regarding the prognostic value of analyzing lymph node DNA from patients with cutaneous T-cell lymphoma for the presence of a monoclonal T-cell population by Southern blot vs polymerase chain reaction (PCR) methods.

Design  Inception cohort study from 1982 to 1998. Recruitment of new patients ended in 1994.

Setting  A tertiary care referral center in Seattle, Wash.

Patients  Fifty-five uniformly staged patients with the diagnosis of cutaneous T-cell lymphoma who underwent a lymph node biopsy, 21 with clinically abnormal nodes and 34 with normal nodes.

Interventions  Lymph nodes were evaluated for T-cell receptor (TCR) {gamma}-chain gene rearrangement by 2 PCR methods: capillary electrophoresis and denaturing gradient gel electrophoresis. The same lymph nodes were evaluated by Southern blot analysis for TCR {beta}-chain gene rearrangement and examined histopathologically on the basis of the National Cancer Institute lymph node classification system. Patients were observed clinically for a mean of9.5 years.

Main Outcome Measures  Skin stage, clinical lymph node examination, lymph node histologic examination, Southern blot analysis, and PCR analyses were evaluated as potential prognostic predictors by univariate and multivariate analyses. The statistical association of TCR analysis and clinical outcome was determined among all patients. Hazard ratios (HRs) by Cox proportional hazards regression analysis were used to estimate the risk of a poor clinical outcome. Cumulative survival rates were analyzed by the Kaplan-Meier method.

Results  A skin stage of T3 (tumors) or T4 (erythroderma) was the most powerful predictor of a poor clinical outcome (HR, 31.3 vs T1; P<.001). Patients with detectable TCR {gamma}-chain gene rearrangement in lymph node DNA by PCR also were more likely to have a poor outcome (HR, 5.1; P<.001), but it was a less powerful predictor than skin stage. Even when the skin stage, presence or absence of lymphadenopathy, and histologic lymph node score were known for the patient, Southern blot analysis still added to prediction of a poor outcome (HR, 9.3; P = .007), whereas PCR provided no statistically significant additional information on outcome.

Conclusions  Detection of a monoclonal T-cell population by PCR in lymph nodes of patients with cutaneous T-cell lymphoma does not enhance prediction of clinical outcome and probability of survival beyond what can be determined from clinical examination and histologic lymph node scores. Skin stage and the presence or absence of lymphadenopathy remain the most important determinants of clinical outcome.


Author Affiliations: UCLA Neuropsychiatric Institute/West Los Angeles Veterans Affairs Medical Center, Los Angeles, Calif (Dr Juarez); Departments of Dermatology, University of Wisconsin, and William S. Middleton Memorial Veterans Affairs Medical Center, Madison (Dr G. S. Wood); Mountain-Whisper-Light Statistical Consulting, Seattle, Wash (Dr Polissar); and Departments of Medicine (Division of Dermatology) (Drs Isenhath, Haycox, and Olerud)and Laboratory Medicine (Drs Sabath and B. Wood and Ms Hanke), University of Washington, Seattle.


RELATED ARTICLE

Beyond Clonal Detection: Defining the T-Cell Clone
Joan Guitart
Arch Dermatol. 2005;141(9):1159-1160.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Olsen et al.
Blood 2007;110:1713-1722.
ABSTRACT | FULL TEXT  

In Search of Prognostic Markers in Mycosis Fungoides
Journal Watch Dermatology 2005;2005:5-5.
FULL TEXT  

Beyond Clonal Detection: Defining the T-Cell Clone
Guitart
Arch Dermatol 2005;141:1159-1160.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.